Indiana University of Medicine researchers said the test can help identify biomarkers in the blood and could actually help in the fight against opioid abuse.
Business - News
Tandem Diabetes Care has received a nod from FDA for the t:slim X2 insulin pump and the approval opens up a new device category – Alternate Controller Enabled Infusion Pumps.
In addition to J&J picking up Auris Health for $3.4 billion, Roger Smith, Phd, who follows the surgical robotics market closely, said we could continue to see large medtech companies making acquisitions in the space.
The AdVance XP Male Sling System has been redesigned for ease of placement and improved stability, the company noted.
The two companies worked together to develop a smart cable and software module, which would enable compatibility between the FORE-SIGHT sensor and the HemoSphere platform.
Acutus Medical originally received a nod from FDA in 2017 and a CE mark in 2016 for the AcQMap cardiac imaging technology.
After spending 2018 dealing with quality control remediation and supply chain issues, Zimmer Biomet expects to return to market growth by 2020.
Edwards might be primarily known for its TAVR systems, but the company has been making some interesting forays into the artificial intelligence realm.
The NAVIGATE study evaluating electromagnetic navigation bronchoscopy (ENB) procedures using the superDimension navigation system to aid in lung cancer diagnosis, staging, and treatment.
The Tempe, AZ-based company has raised $10M in a series A to help further commercialize the Gamma Tile, surgically targeted radiation therapy for patients with brain tumors.
Stryker reported strong performance in the fourth quarter of 2018 with a record number of robots installed and a healthy order book going into 2019.
The Massachusetts Medical Device Development Center is hosting its annual startup competition to identify disruptive medtech and biotech companies. Up to 20 finalists will become eligible to win a share the $200,000 purse of sponsor-provided, in-kind services.
The Marlborough, MA-based company’s device treats benign prostatic hyperplasia, and was obtained when it acquired NxThera for $406 million.